Predictive value of co-existing genetic alterations and tumor mutation burden for patients with completely resected non-small cell lung cancer harboring EGFR mutation: Biomarker analysis of phase III IMPACT study

被引：0
|
作者：
Ikeda, Satoshi
Tsuboi, Masahiro
Sakai, Kazuko
Misumi, Toshihiro
Akamatsu, Hiroaki
Iwamoto, Yasuo
Sakakura, Noriaki
Nakamura, Atsushi
Ohde, Yasuhisa
Hayashi, Hidetoshi
Okishio, Kyoichi
Okada, Morihito
Yoshino, Ichiro
Okami, Jiro
Takahashi, Kazuhisa
Ikeda, Norihiko
Mitsudomi, Tetsuya
Tada, Hirohito
Nakagawa, Kazuhiko
Nishio, Kazuto
机构：
[1] Kanagawa Cardiovasc & Resp Ctr, Yokohama, Kanagawa, Japan
[2] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[3] Kindai Univ, Fac Med, Osakasayama, Japan
[4] Natl Canc Ctr Hosp East, Dept Data Sci, Kashiwa, Chiba, Japan
[5] Wakayama Med Univ, Internal Med 3, Wakayama, Japan
[6] Hiroshima Citizens Hosp, Hiroshima, Japan
[7] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[8] Sendai Kousei Hosp, Sendai, Miyagi, Japan
[9] Shizuoka Canc Ctr, Shizuoka, Sunto Gun, Japan
[10] Natl Hosp Org Kinki Chuo Chest Med Ctr, Sakai, Osaka, Japan
[11] Hiroshima Univ, Hiroshima, Japan
[12] Chiba Univ, Grad Sch Med, Chiba, Japan
[13] Osaka Int Canc Inst, Osaka, Japan
[14] Juntendo Univ, Div Resp Med, Fac Med, Tokyo, Japan
[15] Grad Sch Med, Tokyo, Japan
[16] Tokyo Med Univ, Tokyo, Japan
[17] Suita Tokushukai Hosp, Suita, Osaka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8524
引用
收藏
页数：1
相关论文
共 50 条
  • [41] THE ECONOMIC BURDEN OF METASTATIC NON-SMALL CELL LUNG CANCER IN US PATIENTS WITHOUT AN EGFR OR ALK MUTATION
    Simmons, D.
    Welch, E.
    Pyrih, N.
    Jiang, Z.
    Xiao, Y.
    Jassim, R.
    VALUE IN HEALTH, 2023, 26 (06) : S108 - S108
  • [42] Impact of early progression on prognosis for non-small cell lung cancer patients with EGFR mutation.
    Yoshitsugu, Kanako
    Kenmotsu, Hirotsugu
    Omae, Katsuhiro
    Omori, Shota
    Nakashima, Kazuhisa
    Wakuda, Kazushige
    Ono, Akira
    Naito, Tateaki
    Murakami, Haruyasu
    Takahashi, Toshiaki
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [43] Study of Gefitinib and Pemetrexed as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation
    An, Chaolun
    Zhang, Jiajun
    Chu, Hongjun
    Gu, Chunyan
    Xiao, Feng
    Zhu, Fengwei
    Lu, Rujian
    Shi, Hai
    Zhang, Hongfei
    Yi, Xin
    PATHOLOGY & ONCOLOGY RESEARCH, 2016, 22 (04) : 763 - 768
  • [44] Clinicopathological parameters for circulating tumor DNA shedding in surgically resected non-small cell lung cancer with EGFR or KRAS mutation
    Cho, Min-Sun
    Park, Chul Hwan
    Lee, Sungsoo
    Park, Heae Surng
    PLOS ONE, 2020, 15 (03):
  • [45] Predictive factors in patients with EGFR mutation-negative non-small cell lung cancer treated with erlotinib
    Ishii, Hidenobu
    Azuma, Koichi
    Yamada, Kazuhiko
    Kinoshita, Takashi
    Imamura, Youhei
    Hoshino, Tomoaki
    ONCOLOGY LETTERS, 2014, 8 (06) : 2699 - 2704
  • [46] Poor predictive power of BIM deletion polymorphism for EGFR tyrosine kinase inhibitor outcome in non-small cell lung cancer patients harboring EGFR mutation.
    Lee, June Koo
    Shin, Jong-Yeon
    Kim, Soyeon
    Lee, Sunhwa
    Park, Changho
    Kim, Ji-Yeon
    Koh, Youngil
    Keam, Bhumsuk
    Min, Hye Sook
    Kim, Tae Min
    Jeon, Yoon-Kyung
    Kim, Dong-Wan
    Chung, Doo Hyun
    Heo, Dae Seog
    Lee, Se-Hoon
    Kim, Jong-il
    CANCER RESEARCH, 2013, 73 (08)
  • [47] Feasibility of re-biopsy and EGFR mutation analysis in patients with non-small cell lung cancer
    Kim, Tae-Ok
    Oh, In-Jae
    Kho, Bo Gun
    Park, Ha Young
    Chang, Jin Sun
    Park, Cheol-Kyu
    Shin, Hong-Joon
    Lim, Jung-Hwan
    Kwon, Yong-Soo
    Kim, Yu-Il
    Lim, Sung-Chul
    Kim, Young-Chul
    Choi, Yoo-Duk
    THORACIC CANCER, 2018, 9 (07) : 856 - 864
  • [48] Blood Tumor Mutational Burden as a Predictive Biomarker in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
    Ma, Yuhui
    Li, Quan
    Du, Yaxi
    Cai, Jingjing
    Chen, Wanlin
    Zhao, Guangqiang
    Liu, Xing
    Li, Hongsheng
    Ma, Luyao
    Huang, Yunchao
    Zhou, Yongchun
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [49] Evaluation of gefitinib efficacy according to body surface area in patients with non-small cell lung cancer harboring an EGFR mutation
    Satoshi Igawa
    Masashi Kasajima
    Mikiko Ishihara
    Michiko Kimura
    Yasuhiro Hiyoshi
    Hideyuki Niwa
    Seiichiro Kusuhara
    Shinya Harada
    Maiko Asakuma
    Sakiko Otani
    Ken Katono
    Jiichiro Sasaki
    Noriyuki Masuda
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 939 - 946
  • [50] Evaluation of Two EGFR Mutation Tests on Tumor and Plasma from Patients with Non-Small Cell Lung Cancer
    Kim, Jeong-Oh
    Shin, Jung-Young
    Kim, Seo Ree
    Shin, Kab Soo
    Kim, Joori
    Kim, Min-Young
    Lee, Mi-Ran
    Kim, Yonggoo
    Kim, Myungshin
    Hong, Sook Hee
    Kang, Jin Hyoung
    CANCERS, 2020, 12 (04)
12345